Clinical Study

Different Impacts of Metabolic Syndrome Components on Insulin Resistance in Type 2 Diabetes

Table 2

Comparison of characteristics among the groups of nonmetabolic syndrome (NMS), metabolic syndrome A (MSA), and metabolic syndrome B (MSB).

VariableNMS
(components < 2)  
MSA
(components = 2)  
MSB
(components > 2) 
for trend

Basic data
 HOMA IR*3.2 (1.0)5.3 (4.0)6.1 (3.0)<0.001
 Male/female29/2219/3317/240.10
 Age, year60.9 (10.0)56.4 (9.4)55.8 (10.9)0.01
 FH*, %58.844.256.10.29
 G*, mg/day171.0 (39.3)175.4 (42.0)175.6 (44.6)0.59
 M*, mg/day1731.4 (566)1763.5 (505)1775.6 (727.1)0.24
 BMI*, kg/m224.2 (2.7)27.0 (4.3)27.7 (4.9)<0.001
 WC*, cm82.0 (7.0)87.7 (10.9)92.0 (10.5)<0.001
 HC*, cm91.8 (5.9)97.5 (10.0)99.2 (8.4)<0.001
 SBP*, mmHg130.1 (13.2)135.6 (18.2)143.4 (13.3)<0.001
 DBP*, mmHg75.6 (7.1)80.7 (9.9)86.5 (8.7)<0.001
MSC, yes %
 LWC20.071.280.5<0.001
 HTN7.830.861.0<0.001
 HTG7.838.890.2<0.001
 LHDL43.159.687.8<0.001
Fasting serum factors
 Glucose, mg/dL185.5 (54.5)188.4 (62.9)211.1 (51.3)0.04
 HbA1c, %9.1 (1.8)8.8 (1.5)9.7 (1.5)0.07
 Insulin, IU/mL7.3 (4.5)11.3 (6.8)11.9 (6.1)<0.001
 Adiponectin, μg/mL18.2 (7.3)17.8 (8.4)14.0 (4.8)0.01
Fasting lipoprotein
 Triglyceride, mg/dL107.1 (60.8)176.7 (190.4)297.5 (369.1)<0.001
 Cholesterol, mg/dL171.8 (38.4)171.0 (32.4)193.9 (45.5)0.01
 HDL, mg/dL44.4 (10.0)43.7 (10.2)41.3 (6.3)0.12
 LDL, mg/dL114.8 (29.4)105.0 (32.2)115.5 (38.5)0.99

NMS: nonmetabolic syndrome; MSA: metabolic syndrome A; MSB: metabolic syndrome B; HOMA IR: HOMA insulin resistance index; FH: family history of type 2 diabetes disease; G: gliclazide; M: metformin; BMI: body mass index; WC: waist circumference; HC: hip circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; LWC: large waist circumference; HTN: high blood pressure; HTG: high triglyceride; LHDL: low HDL-cholesterol; HDL: HDL-cholesterol; LDL: LDL-cholesterol.